Supplementary Table S5B from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study

Supplementary Table S5B from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study

<p>Whole-exome sequencing and RNA sequencing analyses of tumor tissue samples at pre-and post-treatment</p>

Furkejuvvon:

Bibliográfalaš dieđut
Váldodahkki:	Takafumi Koyama (15035714) (author)
Eará dahkkit:	Toshio Shimizu (15050147) (author), Yuki Kojima (14182957) (author), Kazuki Sudo (16374908) (author), Hitomi Sumiyoshi Okuma (16540569) (author), Tatsunori Shimoi (16540572) (author), Hitoshi Ichikawa (16540575) (author), Shinji Kohsaka (14957594) (author), Ryo Sadachi (16540578) (author), Akihiro Hirakawa (16540581) (author), Akihiko Yoshida (16540584) (author), Reiko Makihara Ando (16540587) (author), Toshihide Ueno (14946328) (author), Mitsuru Yanagaki (15093837) (author), Naoko Matsui (16540590) (author), Kenichi Nakamura (16540593) (author), Noboru Yamamoto (15013614) (author), Kan Yonemori (15033972) (author)
Almmustuhtton:	2025
Fáttát:	Cancer Cancer Detection and Diagnosis Clinical Research and Trials Methods and Technology Biomarkers Small molecule biomarkers Clinical Trial Results Phase II clinical trials Liquid Biopsy Sarcomas Soft-tissue sarcoma
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Lasit vuosttaš kommeantta. Visot kommeanttat leat almmolaččat.!